Morning vs. afternoon: timing of immunotherapy may impact lung cancer outcomes
NCT ID NCT07251582
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether getting immunotherapy in the morning or afternoon changes how well it works for people with stage II-III lung cancer before surgery. About 156 participants will receive standard treatment plus immunotherapy at different times of day. The goal is to see which timing leads to better tumor shrinkage and longer survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE STAGE II-III NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hunan Cancer hospital
RECRUITINGChangsha, Hunan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hunna Cancer Hospital, Clinical Trails Center
RECRUITINGChangsha, Hunan, 410013, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact